The ROE as of September 2024 (TTM) for Codexis, Inc. (CDXS) is -95.80%

According to Codexis, Inc.’s latest financial reports and current stock price. The company's current ROE is -95.80%. This represents a change of 291.02% compared to the average of -24.50% of the last 4 quarters.

Codexis, Inc. (CDXS) Historical ROE (quarterly & annually)

How has CDXS ROE performed in the past?

The mean historical ROE of Codexis, Inc. over the last ten years is -41.30%. The current -95.80% ROE has changed 131.95% with respect to the historical average. Over the past ten years (40 quarters), CDXS's ROE was at its highest in in the September 2015 quarter at 23.14%. The ROE was at its lowest in in the March 2017 quarter at -63.87%.

Codexis, Inc. (CDXS) ROE by Quarter and Year

Discovering the peaks and valleys of Codexis, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Codexis, Inc. (CDXS) Average ROE

How has CDXS ROE performed in the past?

The current ROE of Codexis, Inc. (CDXS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Codexis, Inc. (CDXS) ROE vs. Peers

How is CDXS’s ROE compared to its peers?

Codexis, Inc.’s ROE is greater than Nuvation Bio Inc. (-98.79%), greater than Lyell Immunopharma, Inc. (-33.35%), greater than Century Therapeutics, Inc. (-65.37%), greater than Generation Bio Co. (-92.86%), greater than Shattuck Labs, Inc. (-68.65%), less than Foghorn Therapeutics Inc. (140.34%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Kymera Therapeutics, Inc. (-28.88%), greater than Nurix Therapeutics, Inc. (-67.78%), greater than Kezar Life Sciences, Inc. (-54.50%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than Nkarta, Inc. (-28.83%), greater than NGM Biopharmaceuticals, Inc. (-76.46%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than Revolution Medicines, Inc. (-34.57%),

Build a custom stock screener for Codexis, Inc. (CDXS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Codexis, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Codexis, Inc. (CDXS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Codexis, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.